The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in ...

The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31 ...

The DPP-IV inhibitors are a very new class of drugs, and they are taken as pills. The way that they work is by decreasing the breakdown of a substance you make yourself -- everyone makes it.

Adults using a DPP-IV inhibitor had a similar risk for diabetic macular edema as those not using a DPP-IV. Of 957 adults in the GLP-1 analysis, 13.6% developed diabetic macular edema.

The drug, LAF237, is the first in a new class of agents known as dipeptidyl peptidase IV (DPP-4) inhibitors. Unlike exenatide (Exendin-4), a synthetic version of GLP-1, LAF237 inhibits the action ...

That drug holds promise as a monotherapy, Merck said, but its brightest future may come as a fixed-dose partner to a DPP-4 blocker, and the pair is working to prove that hypothesis.

DPP-4 inhibitors are prescribed to lower blood sugar levels in adults with type 2 diabetes. This drug class is available as a standalone therapy or as a combination therapy.

Hongting Zheng, from Xinqiau Hospital and the Third Military Medical University, says that the drugs, belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class—there is a list of FDA ...

Other DPP-IV drugs include Merck's Januvia, which has already won FDA approval, and the now-halted Redona drug from GlaxoSmithKline .

The authors conclude that while DPP-4 inhibitor use may not be associated with an increased risk in CAP hospitalization, more research would need to be conducted to see if these drugs increase the ...